NASDAQ:MCRB

Seres Therapeutics Stock Forecast, Price & News

$6.91
+0.17 (+2.52 %)
(As of 09/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.77
$7.04
50-Day Range
$5.46
$20.83
52-Week Range
$5.41
$38.50
Volume1.17 million shs
Average Volume1.34 million shs
Market Capitalization$633.78 million
P/E RatioN/A
Dividend YieldN/A
Beta3.98
30 days | 90 days | 365 days | Advanced Chart
Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Seres Therapeutics logo

About Seres Therapeutics

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

249th out of 1,352 stocks

Pharmaceutical Preparations Industry

118th out of 665 stocks

Analyst Opinion: 4.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Seres Therapeutics?

Wall Street analysts have given Seres Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seres Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Seres Therapeutics
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its quarterly earnings data on Tuesday, August, 3rd. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.12. The biotechnology company earned $5.26 million during the quarter, compared to the consensus estimate of $4.40 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 87.12% and a negative net margin of 441.65%.
View Seres Therapeutics' earnings history
.

How has Seres Therapeutics' stock been impacted by COVID-19?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 161.7% and is now trading at $6.91.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MCRB?

7 brokers have issued 1 year price objectives for Seres Therapeutics' stock. Their forecasts range from $7.00 to $32.00. On average, they anticipate Seres Therapeutics' stock price to reach $20.83 in the next year. This suggests a possible upside of 201.5% from the stock's current price.
View analysts' price targets for Seres Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:
  • Eric D. Shaff, President, Chief Executive Officer & Director
  • David A. Arkowitz, EVP, Chief Financial & Accounting Officer
  • Matthew R. Henn, Chief Scientific Officer & Executive VP
  • Barbara McGovern, Vice President-Medical Affairs
  • Kelly M. Brady, Vice President-Clinical Operations

Who are some of Seres Therapeutics' key competitors?

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), The Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Flagship Pioneering Inc. (15.68%), FMR LLC (14.09%), ARK Investment Management LLC (10.59%), BlackRock Inc. (7.00%), Sumitomo Mitsui Trust Holdings Inc. (5.77%) and Nikko Asset Management Americas Inc. (5.76%).
View institutional ownership trends for Seres Therapeutics
.

Which institutional investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Federated Hermes Inc., Flagship Pioneering Inc., Goldman Sachs Group Inc., Squarepoint Ops LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Seres Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Seres Therapeutics stock?

MCRB stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., FMR LLC, Morgan Stanley, Morgan Stanley, BlackRock Inc., Lord Abbett & CO. LLC, Integral Health Asset Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Seres Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $6.91.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $633.78 million and generates $33.22 million in revenue each year. The biotechnology company earns $-89,130,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 155 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

Where are Seres Therapeutics' headquarters?

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 945-9626 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.